Cyted Health
Cyted Health is a Cambridge University spin-out that commercializes the FDA 510(k)-cleared EndoSign capsule sponge device combined with methylation biomarker assays and AI-assisted pathology screening for non-endoscopic early detection of Barrett's Esophagus and esophageal cancer, serving NHS providers in the UK and US healthcare systems.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Cyted Health does
Cyted Health is a Cambridge University spin-out (founded 2017) that develops and commercializes the EndoSign capsule sponge — a minimally invasive, FDA 510(k)-cleared cell collection device that patients swallow and that collects pan-esophageal samples in under ten minutes without sedation. The device feeds a laboratory-based diagnostic pipeline comprising methylation biomarker assays and AI-assisted pathology screening, with the latter developed in collaboration with Microsoft Research and shown to cut pathologist workload by up to 63%. Test interpretation is delivered through Cyted's UKAS ISO 15189:2022-accredited UK laboratory and CLIA-certified, CAP-accredited US laboratory.
The company's commercial business model is a transaction-based diagnostic testing service sold primarily to public healthcare systems — principally NHS hospitals, GP surgeries, and community care pathways in England, Scotland, and Wales — for early detection of Barrett's Esophagus and esophageal adenocarcinoma in patients with chronic GERD and heartburn. NHS Scotland has implemented EndoSign nationally since 2020 as a triage tool, and 35,000+ tests have been completed across 60+ NHS sites, with documented outcomes including a 77% reduction in follow-up endoscopy demand and £421+ per-patient cost savings versus standard endoscopy pathways. Multiple clinical programs — including the BEST4 UK screening trial, DETECT-ME US validation study, CYTOPRIME 2 community-care study, and QuBIE eosinophilic esophagitis study — support both label expansion and reimbursement evidence.
Cyted Health is a private UK-headquartered company that closed a $44 million Series B first tranche in August 2025 led by EQT Life Sciences and co-led by Advent Life Sciences and the British Business Bank, with the explicit intent of accelerating US commercial expansion. Strategic leadership additions — US President Betsy Hanna, Board Chair Gail Marcus (also on Natera's board), and Strategic Advisor Chris Freeman (former CCO of Guardant Health) — are oriented toward building US payer, provider, and commercial infrastructure on top of the FDA 510(k) clearance secured in February 2024.
Cyted Health firmographics
Firmographics- Name
- Cyted Health
- Legal name
- Cyted Ltd
- Website
- https://cytedhealth.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cyted Health is a Cambridge University spin-out that commercializes the FDA 510(k)-cleared EndoSign capsule sponge device combined with methylation biomarker assays and AI-assisted pathology screening for non-endoscopic early detection of Barrett's Esophagus and esophageal cancer, serving NHS providers in the UK and US healthcare systems.
- Ownership category
- akta.pro rank
Cyted Health industry classification
Industry- Product category
- Gastrointestinal Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics) (HLAHAAAE)
- akta.pro secondary industries
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI)
Keywords
Where Cyted Health is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Cyted Health business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Diagnostic Testing Services: Cyted Health generates revenue through providing diagnostic testing services using the EndoSign capsule sponge device combined with molecular biomarker analysis. Healthcare providers (primarily NHS in UK) pay for tests that enable early detection of esophageal conditions including Barrett's Esophagus and esophageal cancer.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | NHS England reimbursement rate |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Cyted Health product offering
Product offeringCore offering
Cyted Health develops and delivers non-endoscopic gastrointestinal diagnostics centered on its FDA 510(k)-cleared EndoSign capsule sponge cell collection device paired with molecular biomarker analysis (methylation assays including TFF3) and AI-powered pathology screening. The company operates accredited laboratory services in the UK (UKAS ISO 15189:2022) and the US (CLIA-certified and CAP-accredited) that process collected samples for the early detection of Barrett's Esophagus and esophageal cancer. Cyted Health sells these diagnostic testing services to NHS hospitals and GP networks in the UK and to US healthcare providers, including through the Heartburn Health Check community pathway.
Product overview
Cyted Health operates a diagnostic platform centered on EndoSign®, combining a non-endoscopic capsule sponge device with advanced molecular diagnostics. The EndoSign® cell collection device collects esophageal samples which are then analyzed in Cyted's accredited laboratories (UK and US) using methylation biomarker analysis and AI-powered pathology screening. The company offers laboratory services, molecular diagnostic tests, and is running multiple clinical validation studies including DETECT-ME (US), BEST4 (UK screening), and CYTOPRIME 2 (community care).
Differentiator
Problem solved
Functional benefit
Brands
- EndoSign: FDA 510(k)-cleared non-endoscopic capsule sponge device for cell collection and molecular diagnostics for Barrett's Esophagus and esophageal cancer detection
- Heartburn Health Check
- DETECT-ME
Products and services
- EndoSign® Cell Collection Device FDA 510(k)-cleared non-endoscopic capsule sponge device that enables safe and accessible esophageal cell collection with full esophageal sampling. The procedure takes less than ten minutes, does not require sedation, and is used by healthcare providers for the early detection of Barrett's Esophagus and esophageal adenocarcinoma.
- Cyted Laboratory Services Accredited laboratory services in the UK (UKAS ISO 15189:2022) and US (CLIA-certified and CAP-accredited) delivering high-quality molecular diagnostic testing and clinically actionable results for esophageal conditions, including methylation biomarker analysis and AI-assisted pathology screening.
- Heartburn Health Check Diagnostic pathway using the EndoSign capsule sponge test for adults with chronic gastroesophageal reflux disease (GERD) and heartburn symptoms, enabling community-based screening for Barrett's Esophagus and esophageal cancer.
Quantifiable outcome
- 77% reduction in follow-up endoscopy demand when using capsule sponge testing
- +6 more outcomes
Companies that use Cyted Health
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Cyted Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
Cyted Health partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and supporting.
- NHS ScotlandcoreNational implementation partnership for capsule sponge testing since 2020. NHS Scotland adopted EndoSign as a triage tool during COVID-19 to address endoscopy backlog. Over 6,000 tests performed with demonstrated 77% reduction in follow-up endoscopies.
- Chris Freeman (Strategic Advisor)supportingFormer Chief Commercial Officer of Guardant Health appointed as Strategic Advisor to advise on growth and US commercialization strategies. Brings expertise in large-scale commercialization across healthcare sector.
- Microsoft ResearchcoreCollaboration to develop AI models for efficient screening of cancer cells. Microsoft Research contributed machine learning expertise using weakly supervised deep learning in histopathology, reducing pathologist workload by up to 63%. Research published in Nature Communications.
- Devyser Genomic LaboratoriessupportingPartnership for laboratory analyses to support FDA 510(k) cleared EndoSign device commercialization in US market. Devyser conducts the lab analyses for diagnostic testing services.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Cyted Health competitors and assessment
Company assessmentBroad incumbents
- Fujifilm Healthcare: Fujifilm's healthcare division provides endoscopy systems and AI-augmented imaging solutions that compete with Cyted's value proposition of avoiding endoscopy. A large incumbent in the diagnostic and procedural GI space.
- Pentax Medical (HOYA): Pentax Medical manufactures endoscopy systems and is one of the three major endoscopy incumbents (with Olympus and Fujifilm). Its installed endoscopy base represents the alternative pathway Cyted aims to triage and reduce demand for.
- Guardant Health: Guardant Health is a publicly listed precision oncology company specializing in liquid biopsy and molecular diagnostics. Its commercial scale, Nasdaq listing, and Strategic Advisor connection (Chris Freeman) make it a relevant comparable for Cyted's US commercialization trajectory in molecular oncology diagnostics.
- Exact Sciences: Exact Sciences is a publicly listed cancer diagnostics leader with Cologuard for colorectal cancer screening and an active pipeline in multi-cancer detection. While not a direct esophageal competitor, it represents a large public-market comparable for Cyted's cancer-screening platform strategy and commercial scaling.
- Olympus Corporation: Olympus is the global market leader in endoscopy equipment — the standard-of-care alternative to Cyted's capsule sponge approach. As Cyted positions EndoSign as a triage tool to reduce endoscopy demand, Olympus's installed base, R&D scale, and transnasal endoscopy investments represent the dominant incumbent Cyted must displace or partner with.
Others
- Medtronic: Medtronic (through its Barrx acquisition) provides radiofrequency ablation systems for treating Barrett's Esophagus after diagnosis — sitting downstream of Cyted's diagnostic step. While not a direct diagnostic competitor, Medtronic is a major incumbent in the broader Barrett's Esophagus care pathway.
- Devyser: Devyser Genomic Laboratories is Cyted's existing US laboratory partner, performing the molecular analyses supporting EndoSign commercialization. While not a competitor, it is a direct ecosystem participant and adjacent diagnostics-services peer.
Direct peers
- Lucid Diagnostics: Lucid Diagnostics (a subsidiary of PAVmed) commercializes the EsoCheck capsule collection device combined with the EsoGuard methylation biomarker assay for non-endoscopic detection of Barrett's Esophagus and esophageal cancer — directly competing with Cyted's EndoSign platform in the same indication, same patient population, and same clinical pathway.
- CDx Diagnostics: CDx Diagnostics offers the WATS3D (Wide-Area Transepithelial Sampling) brush biopsy platform for esophageal dysplasia and Barrett's detection. While the collection modality differs, CDx is a direct competitor in non-endoscopic or minimally invasive esophageal diagnostics targeting the same gastroenterology customers.
Emerging players
- Interpace Biosciences: Interpace Biosciences offers molecular diagnostics for esophageal and thyroid cancers, including assays used in Barrett's Esophagus risk stratification. It is a smaller emerging player with partial overlap in the esophageal diagnostics market served by Cyted.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cyted Health social profiles
Digital presenceCyted Health compliance and trust
Trust signalCompliance5 records
Cyted Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cyted Health leadership team
Management profileNumber of profiles
Profiles18 records
Cyted Health subsidiaries and ownership
Company hierarchySubsidiaries2 records
Cyted Health funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cyted Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cyted Health
What does Cyted Health do?
Cyted Health develops and delivers non-endoscopic gastrointestinal diagnostics centered on its FDA 510(k)-cleared EndoSign capsule sponge cell collection device paired with molecular biomarker analysis (methylation assays including TFF3) and AI-powered pathology screening. The company operates accredited laboratory services in the UK (UKAS ISO 15189:2022) and the US (CLIA-certified and CAP-accredited) that process collected samples for the early detection of Barrett's Esophagus and esophageal cancer. Cyted Health sells these diagnostic testing services to NHS hospitals and GP networks in the UK and to US healthcare providers, including through the Heartburn Health Check community pathway.
Is Cyted Health a public or private company?
Cyted Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cyted Health founded?
Cyted Health was founded in 2017. It employs 51 to 100 people.
Where is Cyted Health based?
Cyted Health is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Cyted Health make money?
One revenue line is on record: diagnostic Testing Services.
Who are Cyted Health's main competitors?
Broad incumbents on record are Fujifilm Healthcare, Pentax Medical (HOYA), Guardant Health, Exact Sciences and Olympus Corporation. Others are Medtronic and Devyser. Direct peers are Lucid Diagnostics and CDx Diagnostics. Interpace Biosciences is listed as an emerging player.
Does Cyted Health have an API?
No public API is recorded for Cyted Health.
What industry is Cyted Health in?
Cyted Health's product category is Gastrointestinal Diagnostics. Its primary akta.pro industry code is HLAHAAAE, Anatomic Pathology & Histology/Cytology IVD (Tissue Diagnostics), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.